Abstract: A process to form a HEMT can have a gate electrode layer that initially has a plurality of spaced-apart doped regions. In an embodiment, any of the spaced-apart doped regions can be formed by depositing or implanting p-type dopant atoms. After patterning, the gate electrode can include an n-type doped region over the p-type doped region. In another embodiment a barrier layer can underlie the gate electrode and include a lower film with a higher Al content and thinner than an upper film. In a further embodiment, a silicon nitride layer can be formed over the gate electrode layer and can help to provide Si atoms for the n-type doped region and increase a Mg:H ratio within the gate electrode. The HEMT can have good turn-on characteristics, low gate leakage when in the on-state, and better time-dependent breakdown as compared to a conventional HEMT.

Abstract: The present disclosure relates to a holder for attaching an optical component to a structure such as a tray. The holder includes integrated first mounting features including end tabs and integrated second mounting features including dovetail projections.

Abstract: As solution for predistorting a signal is presented. The solution comprises receiving (600) as an input a signal comprising at least two signal components on a different band, sampling (602) the input signal comprising linear terms, composite non-linear terms causing intermodulation outside Nyquist band of the input signal and further non-linear terms causing intermodulation inside the Nyquist band, the further non-linear terms comprising multi-band terms. Oversampling (604) by a given factor is applied to the signal in a first predistortion circuit for processing the linear terms and composite non-linear terms causing intermodulation outside Nyquist band; processing (606) the input signal without oversampling in a second predistortion circuit in parallel with the first predistortion circuit for the further non-linear terms. The rates of the output signals of the predistortion circuits are matched (608), combined and filtered (610).

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: Compositions that comprise salts, compounds and complexes of 64Zn-enriched zinc, such as 64Zn-enriched zinc aspartate, and further optionally include 85Rb-enriched rubidium salt compounds of general formula 1, below, wherein each of R1 through R14 is independently selected from H, OH, F, Cl, Br, I, C1-C6 alkyl, C1-C6 alkoxy, and NO2, such as the compound of Formula 1 in which R3 is CH3 and all other R groups are H for use to treat a neurodegenerative disease (NDD), such as Parkinson's disease (PD). Methods that entail administering such compositions to treat an NDD, such as PD, optionally in combination with any other treatment for an NDD such as for PD.

Abstract: A method of preventing or treating type 2 diabetes comprising administering a therapeutically effective amount of 64Zn-enriched zinc.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Abstract: A method for treating melanoma or preventing the development of melanoma comprising administration of a composition comprising 64Zne(Asp)2 in a therapeutically effective amount. Such administration may be via injection such as intratumoral and/or intravenous injection and may be once a day or more than once a day. A composition for the treatment of or prevention of melanoma comprising 64Zne(Asp)2 in a therapeutically effective amount. The composition may be a liquid suitable for injection.

Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Abstract: This specification relates to digital pre-distortion of signals before power amplification during the transmission of a signal. A method comprising: receiving an input signal 1st and 2nd subband signals associated with 1st and 2nd centre frequencies; applying a pre-distortion to the input signal to generate a pre-distorted signal, the pre-distortion applying an inverse to a power amplification model associated with a power amplifier; and outputting the pre-distorted signal for power amplification. The power amplification model or the inverse to the power amplification model comprises a first plurality of terms and a second plurality of terms. Each of the 1st and 2nd plurality of terms comprising a product of a complex coefficient, a power factor, and other factors depending on if it is 1st or 2nd plurality of terms.

Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Abstract: A method of treating or preventing a disease or condition caused (at least in part) by, or related to, a viral infection in a patient, comprising administering to said patient a pharmaceutical composition comprising, in certain embodiments, 64Zn-enriched zinc, at a therapeutically effective or a prophylactically effective dose for treating or preventing the disease or condition caused by the viral infection.

Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Abstract: A method of preventing or treating type 2 diabetes comprising administering a therapeutically effective amount of Zn-enriched zinc.

Abstract: A method for preventing or treating Nonalcoholic steatohepatitis (NASH) comprising administering a prophylactically or therapeutically effective amount of 64Zn-enriched zinc. The 64Zn-enriched zinc is in the form of a 64Zne (64Zn enriched) compound or a 64Zne salt. In certain embodiments, the disclosed compositions contain zinc that is at least 80% 64Zne, at least 90% 64Zne, at least 95% 64Zne, or at least 99% 64Zne, for example, zinc that is 80% 64Zne, 85% 64Zne, 90% 64Zne, 95% 64Zne, 99% 64Zne, or 99.9% 64Zne.

Abstract: A method for reducing the weight of an overweight or obese subject comprising administering a therapeutically effective amount of a composition comprising 64Zn-enriched zinc. A method for preventing or reducing weight gain comprising administering an effective amount of a composition comprising 64Zn-enriched zinc.